Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
The offering will be made only by means of a prospectus, copies of which may be obtained by contacting
A registration statement relating to these securities has been filed with the
About
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance’s expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the public offering, market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in
complete the public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the public offering, Revance and its business can be found under the heading “Risk Factors” in the prospectus included in Revance’s Registration Statement on Form S-1 (File No. 333-196582), initially filed with the
herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT:Westwicke Partners , Investor RelationsLynn Pieper 415-202-5678 lynn.pieper@westwicke.com
Source:
News Provided by Acquire Media